Logo image of MCRB

SERES THERAPEUTICS INC (MCRB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MCRB - US81750R2013 - Common Stock

15 USD
+0.08 (+0.54%)
Last: 12/30/2025, 10:21:12 AM
Fundamental Rating

2

Overall MCRB gets a fundamental rating of 2 out of 10. We evaluated MCRB against 530 industry peers in the Biotechnology industry. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability. MCRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MCRB has reported negative net income.
MCRB had a negative operating cash flow in the past year.
In the past 5 years MCRB reported 4 times negative net income.
MCRB had negative operating cash flow in 4 of the past 5 years.
MCRB Yearly Net Income VS EBIT VS OCF VS FCFMCRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of 3.76%, MCRB belongs to the top of the industry, outperforming 90.19% of the companies in the same industry.
MCRB's Return On Equity of 12.34% is amongst the best of the industry. MCRB outperforms 93.40% of its industry peers.
Industry RankSector Rank
ROA 3.76%
ROE 12.34%
ROIC N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCRB Yearly ROA, ROE, ROICMCRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

MCRB has a Profit Margin of 1536.75%. This is amongst the best in the industry. MCRB outperforms 99.43% of its industry peers.
The Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 1536.75%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCRB Yearly Profit, Operating, Gross MarginsMCRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for MCRB has been increased compared to 1 year ago.
MCRB has more shares outstanding than it did 5 years ago.
MCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MCRB Yearly Shares OutstandingMCRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MCRB Yearly Total Debt VS Total AssetsMCRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MCRB has an Altman-Z score of -10.66. This is a bad value and indicates that MCRB is not financially healthy and even has some risk of bankruptcy.
MCRB's Altman-Z score of -10.66 is on the low side compared to the rest of the industry. MCRB is outperformed by 73.58% of its industry peers.
There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.66
ROIC/WACCN/A
WACCN/A
MCRB Yearly LT Debt VS Equity VS FCFMCRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
The Current ratio of MCRB (2.30) is worse than 73.02% of its industry peers.
A Quick Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.30, MCRB is doing worse than 70.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
MCRB Yearly Current Assets VS Current LiabilitesMCRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

MCRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.57%, which is quite impressive.
EPS 1Y (TTM)73.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MCRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y103.73%
EPS Next 2Y24.24%
EPS Next 3Y12.91%
EPS Next 5Y21.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MCRB Yearly Revenue VS EstimatesMCRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 50M 100M 150M
MCRB Yearly EPS VS EstimatesMCRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MCRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MCRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCRB Price Earnings VS Forward Price EarningsMCRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCRB Per share dataMCRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

MCRB's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.24%
EPS Next 3Y12.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MCRB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SERES THERAPEUTICS INC

NASDAQ:MCRB (12/30/2025, 10:21:12 AM)

15

+0.08 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners23.59%
Inst Owner Change-6.97%
Ins Owners0.38%
Ins Owner Change0.71%
Market Cap135.75M
Revenue(TTM)351.00K
Net Income(TTM)5.39M
Analysts78
Price Target21.42 (42.8%)
Short Float %12.52%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.64%
Min EPS beat(2)-28%
Max EPS beat(2)10.71%
EPS beat(4)2
Avg EPS beat(4)-101.12%
Min EPS beat(4)-437.4%
Max EPS beat(4)50.19%
EPS beat(8)5
Avg EPS beat(8)-46.98%
EPS beat(12)6
Avg EPS beat(12)-33.14%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)31.25%
PT rev (3m)-48.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)635.75%
EPS NY rev (3m)135.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 386.75
P/FCF N/A
P/OCF N/A
P/B 3.11
P/tB 3.11
EV/EBITDA N/A
EPS(TTM)-6.29
EYN/A
EPS(NY)-8.85
Fwd EYN/A
FCF(TTM)-2.58
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0.04
BVpS4.83
TBVpS4.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.76%
ROE 12.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1536.75%
GM N/A
FCFM N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.34%
Cap/Sales 89.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -10.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.28%
Cap/Depr(5y)90.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.37%
EPS Next Y103.73%
EPS Next 2Y24.24%
EPS Next 3Y12.91%
EPS Next 5Y21.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.86%
EBIT Next 3Y9.36%
EBIT Next 5YN/A
FCF growth 1Y82.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.22%
OCF growth 3YN/A
OCF growth 5YN/A

SERES THERAPEUTICS INC / MCRB FAQ

What is the ChartMill fundamental rating of SERES THERAPEUTICS INC (MCRB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MCRB.


What is the valuation status of SERES THERAPEUTICS INC (MCRB) stock?

ChartMill assigns a valuation rating of 0 / 10 to SERES THERAPEUTICS INC (MCRB). This can be considered as Overvalued.


What is the profitability of MCRB stock?

SERES THERAPEUTICS INC (MCRB) has a profitability rating of 2 / 10.


How financially healthy is SERES THERAPEUTICS INC?

The financial health rating of SERES THERAPEUTICS INC (MCRB) is 5 / 10.